Holen Sie sich die Stockscreener-App
0.3563
0.20%
0.00035
Biodesix Inc Aktie (BDSX) Neueste Nachrichten
Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting | BDSX Stock News - GuruFocus
Biodesix to Present New Data on Host Immune Classifier for NSCLC at 2025 ASCO Annual Meeting - Nasdaq
Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting - GlobeNewswire
Game-Changing Cancer Test Triples Survival Rate: New Clinical Data Transforms Lung Cancer Treatment - Stock Titan
Biodesix (BDSX) Target Price Reduced to $2 by Scotiabank | BDSX Stock News - GuruFocus
Biodesix Jumps 46% As Insider Buying, Retail Optimism Offset Scotiabank Target Cut By Stocktwits - Investing.com India
Scotiabank cuts Biodesix stock target to $2, maintains outlook By Investing.com - Investing.com Canada
Biodesix Approves Reverse Stock Split at Annual Meeting - TipRanks
Scotiabank cuts Biodesix stock target to $2, maintains outlook - Investing.com
Biodesix (BDSX) Sees Target Price Lowered by Scotiabank | BDSX S - GuruFocus
Biodesix to Participate in Upcoming Investor Conferences | BDSX Stock News - GuruFocus
Biodesix to Participate in Upcoming Investor Conferences - GlobeNewswire
Biodesix Executives Set for Major Investor Conferences: William Blair and Craig-Hallum Presentations Ahead - Stock Titan
Director’s Massive Stock Purchase Signals Confidence in Biodesix! - TipRanks
Biodesix's (BDSX) "Market Perform" Rating Reaffirmed at William Blair - MarketBeat
Craig Hallum Cuts Biodesix (NASDAQ:BDSX) Price Target to $1.50 - Defense World
Biodesix revises 2025 revenue guidance to $80M–$85M amid sales force reconfiguration and primary care expansion - MSN
Susquehanna International Group LLP Grows Stock Holdings in Biodesix, Inc. (NASDAQ:BDSX) - MarketBeat
Biodesix, Inc. (NASDAQ:BDSX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - Yahoo Finance
Biodesix, Inc. Earnings Call: Growth Amid Challenges - TipRanks
Biodesix, Inc. (NASDAQ:BDSX) Q1 2025 Earnings Call Transcript - MSN
Analysts Just Slashed Their Biodesix, Inc. (NASDAQ:BDSX) EPS Numbers - simplywall.st
Biodesix Announces New Clinical and Economic Data for Its Nodify Lung® Tests At ISPOR and ATS - marketscreener.com
News Flash: 6 Analysts Think Biodesix, Inc. (NASDAQ:BDSX) Earnings Are Under Threat - Yahoo Finance
Biodesix Announces New Clinical and Economic Data for its Nodify Lung® Tests at ISPOR and ATS | BDSX Stock News - GuruFocus
Biodesix, Inc. to Present New Data on Lung Cancer Diagnosis and Testing at ISPOR and ATS 2025 Conferences - Nasdaq
Biodesix Announces New Clinical and Economic Data for its Nodify Lung® Tests at ISPOR and ATS - GlobeNewswire
New Clinical Data: Biodesix Lung Cancer Tests Could Prevent 60% of Unnecessary Invasive Procedures - Stock Titan
Denver Post Names Biodesix a Winner of Top Workplaces 2025 Award - GlobeNewswire
Biodesix Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
Craig-Hallum Adjusts Price Target for Biodesix (BDSX) | BDSX Sto - GuruFocus
Diagnostic Leader Biodesix Clinches Elite Colorado Workplace Award, Employee Survey Reveals Why - Stock Titan
Biodesix stock plunges as life-sciences firm cuts sales projection - BizWest
Biodesix (BDSX): Analyst Maintains Buy Rating Despite Lowered Pr - GuruFocus
Biodesix (BDSX) Target Price Lowered by Lake Street Analyst | BD - GuruFocus
Canaccord cuts Biodesix stock target to $1.50, keeps buy rating By Investing.com - Investing.com Nigeria
Biodesix stock target cut to $2 by TD Cowen, retains buy rating - Investing.com
Biodesix, Inc. (BDSX) Reports Q1 Loss, Misses Revenue Estimates - MSN
Biodesix (BDSX) Target Price Lowered by Lake Street Analyst | BDSX Stock News - GuruFocus
Biodesix Inc Reports Q1 2025 Earnings: EPS of -$0.08 Misses Esti - GuruFocus
Biodesix stock rating cut to Market Perform at William Blair By Investing.com - Investing.com South Africa
BDSX: Canaccord Genuity Lowers Price Target for Biodesix | BDSX Stock News - GuruFocus
Canaccord cuts Biodesix stock target to $1.50, keeps buy rating - Investing.com Australia
BDSX Reports Q1 Revenue Below Expectations, Highlights Strategic - GuruFocus
Biodesix price target lowered to $1.50 from $2.50 at Canaccord - TipRanks
Biodesix (BDSX) Price Target Reduced as 2025 Revenue Outlook Dec - GuruFocus
Biodesix price target lowered to $1.50 from $3 at Craig-Hallum - TipRanks
Biodesix price target lowered to $2 from $3 at TD Cowen - TipRanks
Biodesix (BDSX) Downgraded to Market Perform by William Blair | - GuruFocus
Biodesix (BDSX) Target Price Reduced to $2 Amid Revenue Challeng - GuruFocus
Biodesix (BDSX) Price Target Reduced as 2025 Revenue Outlook Declines | BDSX Stock News - GuruFocus
Biodesix price target lowered to $2 from $3 at Lake Street - TipRanks
William Blair Downgrades Biodesix to Market Perform From Outperform - marketscreener.com
Biodesix earnings missed by $0.01, revenue fell short of estimates - Investing.com Nigeria
Biodesix (BDSX) Price Target Reduced Amid Revenue Concerns | BDS - GuruFocus
Biodesix (BDSX) Price Target Reduced Amid Revenue Concerns | BDSX Stock News - GuruFocus
It's Unlikely That Biodesix, Inc.'s (NASDAQ:BDSX) CEO Will See A Huge Pay Rise This Year - simplywall.st
Biodesix (BDSX) Faces Downgrade Amid Revenue Guidance Reduction - GuruFocus
Biodesix stock rating cut to Market Perform at William Blair - Investing.com
0.65%
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):